Facioscapulohumeral muscular dystrophy 2

MONDO:0008031

Any facioscapulohumeral muscular dystrophy in which the cause of the disease is a mutation in the SMCHD1 gene.

Also known as: SMCHD1 facioscapulohumeral muscular dystrophy, facioscapulohumeral muscular dystrophy 2, facioscapulohumeral muscular dystrophy caused by mutation in SMCHD1, facioscapulohumeral muscular dystrophy type 2, fascioscapulohumeral muscular dystrophy 2, digenic, digenic dominant, FSHD2, Fshd2, digenic, facioscapulohumeral muscular dystrophy 2, digenic

13 clinical trials for this condition and its sub-types, 8 tagged with Facioscapulohumeral muscular dystrophy 2 itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Facioscapulohumeral muscular dystrophy (40)

Including sub-types (13) Tagged with Facioscapulohumeral muscular dystrophy 2 (8)

Trials to join now! 10 Not yet finished but already full! 1 Completed 1 Terminated 1

New hope for FSHD: Long-Term drug safety trial underway

Disease control Ongoing

This study is for people with FSHD, a genetic disease that causes muscle weakness. It tests the long-term safety and how well the body tolerates a drug called AOC 1020, given through a vein. About 84 adults who completed a previous study will take part. The main goal is to check …

Phase 2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control

Last updated Jul 16, 2026 00:00 UTC

Facioscapulohumeral muscular dystrophy 2

Where it sits in the disease tree

New hope for FSHD: Long-Term drug safety trial underway